{"id":"NCT02968173","sponsor":"AbbVie","briefTitle":"A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus","officialTitle":"A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-09","primaryCompletion":"2017-07-13","completion":"2017-07-13","firstPosted":"2016-11-18","resultsPosted":"2018-03-13","lastUpdate":"2018-03-13"},"enrollment":50,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Respiratory Syncytial Virus (RSV)"],"interventions":[{"type":"DRUG","name":"Palivizumab","otherNames":["Synagis"]}],"arms":[{"label":"Children at High Risk of severe RSV Infection","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3b, prospective, multicenter, open-label, non-controlled study to assess the safety and effectiveness of immunoprophylaxis with the intramuscular (IM) administration of the liquid formulation of palivizumab for the prevention of RSV hospitalizations in infants at high risk (infants born at less than or equal to 35 weeks gestational age and less than or equal to 6 months of age at enrollment; or infants less than or equal to 24 months of age with a diagnosis of chronic lung disease \\[CLD\\] of prematurity requiring on-going medical treatment within the previous 6 months or infants less than or equal to 24 months of age with hemodynamically significant congenital heart disease \\[CHD\\]).","primaryOutcome":{"measure":"Percentage of Participants With RSV Hospitalization","timeFrame":"Approximately 6 months","effectByArm":[{"arm":"Children at High Risk of Severe RSV Infection","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://dailymed.nlm.nih.gov/dailymed/about.cfm"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":50},"commonTop":[]}}